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MEDICATION THERAPY MANAGEMENT AND STATIN ADHERENCE 
Introduction 
 
Medication therapy management (MTM) is often defined as a “group of services that optimize 
therapeutic outcomes for individual patients.”1 During a MTM session conducted by pharmacists 
or other health professionals, medication-related problems such as suboptimal dosing and drug 
reactions can be identified and addressed.  
 
One medication-related problem that is addressed by pharmacists is medication adherence. 
Adherence to medication regimens is critical to the management of chronic disease states 
because disease progression typically results simply with the passage of time.
2
 In other words, 
chronic disease state management via medication is all about slowing progression and adherence 
is the vital key to successful pharmacotherapy. Pharmacists are positioned to assess adherence 
with MTM because adherence (or lack thereof) is typically observed by one’s pattern of refills at 
a local pharmacy. 
 
Hyperlipidemia, a risk factor for heart disease, is an example of a disease state in which 
adherence is essential. Besides the burden that hyperlipidemia places on the health system, its 
economic costs are also significant to note as it is a contributor to over $38 billion that is used to 
manage and treat cardiovascular disease.
3
  
 
Along with modifications to diet and exercise, statin therapy is a primary form of treatment as 
there is extensive evidence to support its efficacy in reducing mortality in patients.
4
 Adherence to 
3 
 
statins remains a large problem in patients with hyperlipidemia for reasons such as lack of 
perceived improvement in health, low health literacy, and adverse effects.
5
 This is especially 
relevant since statin adherence is associated with lower medical costs.
6
 Because MTM aims to 
assess medication-related problems such as underuse of therapies, MTM is a viable tool that 
pharmacists and other health professionals can utilize. 
 
Since 2009, a regional chain pharmacy in North Carolina implemented four MTM models that 
have utilized both clinical and dispensing pharmacists in conducting comprehensive medication 
reviews (CMRs) and targeted medication reviews (TMRs). Figure 1 depicts these 4 MTM 
models. Because a significant portion of the patients take statins to control hyperlipidemia, 
pharmacists have worked to ensure that patients remain adherent. 
 
Figure 1: MTM Models 
 
Timeframe Pharmacists Involved MTM Type 
2009 CP CMR and TMR 
2010 CP 
DP 
CMR and TMR 
TMR (encouraged) 
2011 CP 
DP 
CMR, TMR, dispensing 
CMR and TMR (encouraged) 
2012 CP 
DP 
CMR, TMR dispensing 
CMR and TMR (required) 
*Clinical pharmacists: CP; dispensing pharmacists: DP 
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Objectives 
 
The aim of this study is to examine how MTM affects statin adherence in non-adherent patients. 
To date, there are limited studies evaluating MTM’s role in managing hyperlipidemia.7 The 
results from this study may assist in clarifying pharmacists’ future use of MTM. 
 
Methods 
Study Design 
 
This study was a multi-site, retrospective study evaluating claims data for patients taking statin 
medications. The University of North Carolina at Chapel Hill Institutional Review Board 
approved this study’s protocol.  
 
North Carolina Medicare Part D participants who had statins filled in 2012 were included in this 
study. All claims needed to have a status of approved/paid to be evaluated. Exclusion criteria 
included patients on antihyperlipidemics other than statins (including combination products with 
statin component such as Vytorin) and patients with statin prescriptions with no refills after an 
MTM intervention. 
Procedures 
 
A single TMR was the intervention for all patients regardless of their baseline adherence status. 
While many other reasons could prompt a TMR, underuse of statin therapy as demonstrated by a 
patient’s late refills was the primary reason for intervention in this study population. Figure 2 
depicts other reasons that may require a health professional to conduct a TMR. 
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Figure 2: Reasons to Conduct a TMR 
Reason Example 
Drug interaction Patient is recently prescribed phenytoin from 
psychiatrist and has been dabigatran for years. 
Insufficient dose/duration Patient with high risk for cardiovascular 
disease on simvastatin 10 mg.    
Excessive dose/duration  Patient on high dose of transdermal fentanyl 
experiencing signs of respiratory depression. 
Administration technique  Patient with diabetes not rotating injection sites 
when using insulin. 
Adverse drug reaction Patient on lisinopril with dry cough. 
 
Patients seen during calendar year 2012 identified by pharmacists as having underutilized their 
statin therapy (i.e., non-adherent) and having undergone MTM intervention served as the 
intervention group. Adherence was defined by the proportion of days covered (PDC) measure.
8
  
PDC was measured in this study by calculating the total days’ supply of medication and dividing 
that number by the number of days a patient has been on that specific days’ supply as 
demonstrated by refill history. Per the PDC measure for chronic disease states such as diabetes 
and hyperlipidemia, adherence is any value > 0.8. PDC values may vary from 0 (meaning no 
adherence whatsoever) to 1 (complete adherence). 
 
Refill history was analyzed for each patient 3, 6, or 12 months before and after each MTM 
session depending on how many months of data were available per patient. 
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Data Collection and Analysis 
 
All MTM claims from year 2012 were included for analysis. Claims were obtained from a billing 
platform for MTM interventions. After obtaining claims, they were then downloaded onto 
Microsoft Excel spreadsheets where patient information was deidentified. Any statistically 
significant difference in adherence was measured using McNemar’s test. 
 
Results 
 
A total of 297 patients were assessed for eligibility to be included in this study. After applying 
the exclusion criteria, 140 patients were evaluated in terms of their adherence before the MTM 
intervention which provided a power of 0.8208 with a one-sided alpha value of 0.05. The reasons 
for exclusion and number of patients in each exclusion category are outlined in Figure 3.  
 
Figure 3  
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About 48.6% of these patients were non-adherent before an MTM session. As a result of MTM, 
exactly 50% of non-adherent patients (34 out of 68 non-adherent patients) became adherent. 
Table 1 depicts these results for both non-adherent and adherent patients and outlines any 
changes that occurred as a result of the intervention. 
 
Table 1 
 
There was a statistically significant increase in adherence in patients who were non-adherent 
(X
2
=10.52). The data suggests that even one single MTM intervention can positively impact 
adherence rates (p=0.0012). 
 
Regarding patients who were adherent before the intervention, the majority of them (83.3%) 
continued to be adherent to statin therapy. In terms of the entire study population, the total 
adherence rate increased from 51.4% of study participants to 67.1%.   
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Discussion 
 
This study is important in that it evaluated the effects that MTM interventions may have on 
patients with hyperlipidemia. Specifically, this study examines the particular role that MTM has 
on statin adherence in multiple timeframes up to 12 months of therapy. The literature on statin 
adherence suggests that the vast majority of patients initiated on statin therapy tend to be non-
adherent regardless of the medical indication but the literature has not looked specifically into 
how MTM can be used to affect adherence.
6, 9-12
 This study provides a foundation for future 
work examining MTM’s role in increasing rates of statin adherence. 
 
This study’s primary finding that MTM is a viable tool to increase statin adherence in non-
adherent patients is crucial given the role that statin therapy plays in reducing rates of 
cardiovascular heart disease. In addition to clinical benefits that MTM can confer to patients, 
there can arguably be various economic savings that have been already been examined in other 
chronic disease states. In particular, the Asheville Project in North Carolina has already shown 
that pharmacist consultation regarding cardiovascular health can decrease medical costs and 
emergency department visits.
13
 Although there is limited evidence on the cost-effectiveness of 
MTM, there is potential for MTM to decrease significant costs associated with non-adherence to 
statins. 
 
There may be a number of reasons that may explain why even a single MTM session can 
positively impact adherence rates. Studies have demonstrated that common barriers to adherence 
include a multitude of reasons such as low health literacy, impaired cognitive function, adverse 
effects, a misunderstanding of a disease state, and complex medication regimens.
14
 Because 
MTM often addresses these barriers, patients can often improve their adherence through a better 
understanding of their medication.  
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While this study shows an increased adherence rate in non-adherent patients as a result of an 
MTM intervention, there are several limitations.  
 
First, refill history through other pharmacies, physician samples, mail order, and other means of 
obtaining medication were not considered. It has been previously demonstrated that patients 
often engage in polypharmacy, making the measurement of adherence difficult.
15
 While 
pharmacists are trained to inquire about polypharmacy at each MTM visit, for the purpose of this 
study, there was no standardization of each MTM session to assess for polypharmacy.  
 
Second, different timeframes were utilized in the analysis of claims data. Patients were analyzed 
3, 6 or 12 months. Because it is known that adherence can vary even within several months, one 
timeframe would have been much more helpful in assessing the effects of MTM.
16
 However, it is 
important to note that this limitation is largely due to the retrospective study design. 
 
Third, this study may possibly be inadequate in evaluating the long-term effects of MTM. The 
maximum timeframe of analysis was only 12 months, a timeframe that may not be predictive of 
long-term change. Despite the short timeframe, it may also be argued that a patient’s adherence 
at 12 months may be a good predictor of future adherence as there is some evidence to 
demonstrate this.
16
 
 
Finally, there is the issue of the definition of adherence. In the literature, a PDC value > 0.8 is 
sufficient to claim that an individual is adherent in chronic disease states such as hypertension, 
diabetes, and hyperlipidemia. This value may be arbitrary as there were patients that exhibited 
tremendous improvement in their PDC values but were still deemed non-adherent since the value 
was still less than 0.8. Additionally, there were patients that demonstrated a slight decrease in 
adherence but were deemed non-adherent per the PDC definition. Both of these cases serve to 
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illustrate that adherence is a much more nuanced concept than simply meeting a certain numeric 
threshold. 
 
Despite these limitations, the results of this study reveal promising areas of future research. For 
instance, there were patients that exhibited overutilization (i.e., PDC > 1). Overutilization can be 
harmful to patients as the risk of certain adverse effects such as myopathy can increase. Patients 
that demonstrate overutilization may also have impaired hepatic and/or renal function which only 
further exacerbates any experienced side effects.
17
 
 
In the future, other disease states managed by pharmacists are worthy of further consideration 
such as hypertension and diabetes. Similar results found in this study may possibly be seen in 
these disease states as the effectiveness of pharmacist involvement in these disease states has 
been previously been demonstrated in the Asheville Project. Hypertension and diabetes may 
arguably be more complex than hyperlipidemia as a significant number of patients are often are 
multiple medications or on more complex regimens (e.g., insulin), but it is a direction that may 
yield more insight into the role that pharmacists can play in increasing adherence rates. 
 
Future work needs to be done to discern the economic costs of each model and to see which 
model is the most cost-effective. This may allow for further improvement of pharmacy workflow 
to allow for both optimal adherence rates and superior cost savings.  
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Conclusion 
 
This study’s results have shown that MTM is viable tool for increasing adherence to statins in 
non-adherent patients. MTM can increase adherence at various timeframes (i.e., 3-12 months) 
from an intervention and adherence at these points in time may be predictive of long term 
adherence. While this study did not examine the cost-effectiveness of MTM in patients on 
statins, MTM may be one tool for pharmacists to consider to improve patient care and decrease 
medical costs associated with cardiovascular disease. Further research is needed to elucidate the 
optimal model of MTM delivery.  
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